Elvitegravir

Mechanism :

Integrase inhibitor: Inhibition of integrase prevents the integration of HIV-1 DNA into host genomic DNA, blocking the formation of the HIV-1 provirus

Indication :

HIV-1 infection

Contraindications :

No contraindications.

Dosing :

Not specified in children.

Adults:

Administered with concomitant atazanavir and ritonavir or lopinavir and ritonavir:

85 mg once daily.

Administered with concomitant darunavir and ritonavir, fosamprenavir and ritonavir, or tipranavir and ritonavir:

150 mg once daily.

Adverse Effect :

Headache, depression, fatigue, insomnia, suicidal ideation, skin rash, diarrhea, nausea, abdominal pain, dyspepsia, vomiting, immune reconstitution syndrome.

Interaction :

Antacids: May decrease the serum concentration of Elvitegravir.
CYP3A4 Inducers: May increase the metabolism of CYP3A4 Substrates
Darunavir: May increase the serum concentration of Elvitegravir.
Dexamethasone (Systemic): May decrease the serum concentration of Elvitegravir.
Fosphenytoin-Phenytoin: May decrease the serum concentration of Elvitegravir.
Ketoconazole (Systemic): May increase the serum concentration of Elvitegravir.
Voriconazole: May increase the serum concentration of Elvitegravir.
Rifampin: May decrease the serum concentration of Elvitegravir.

Hepatic Dose :

Mild and moderate hepatic impairment: No dosage adjustment needed.
Severe hepatic impairment: Use is not recommended.